TW201722428A - 用於治療急性骨髓性白血病(aml)之醫藥組成物及對有此需要者進行急性骨髓性白血病治療之方法 - Google Patents

用於治療急性骨髓性白血病(aml)之醫藥組成物及對有此需要者進行急性骨髓性白血病治療之方法 Download PDF

Info

Publication number
TW201722428A
TW201722428A TW105134054A TW105134054A TW201722428A TW 201722428 A TW201722428 A TW 201722428A TW 105134054 A TW105134054 A TW 105134054A TW 105134054 A TW105134054 A TW 105134054A TW 201722428 A TW201722428 A TW 201722428A
Authority
TW
Taiwan
Prior art keywords
patient
gene
aml
genes
degree
Prior art date
Application number
TW105134054A
Other languages
English (en)
Chinese (zh)
Inventor
中丸健治
田崎康一
關剛彥
奈奇亞契 席
邁克爾 安德瑞夫
石澤丈
Original Assignee
第一三共股份有限公司
美國德州系統大學評議委員會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共股份有限公司, 美國德州系統大學評議委員會 filed Critical 第一三共股份有限公司
Publication of TW201722428A publication Critical patent/TW201722428A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105134054A 2015-10-23 2016-10-21 用於治療急性骨髓性白血病(aml)之醫藥組成物及對有此需要者進行急性骨髓性白血病治療之方法 TW201722428A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245667P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
TW201722428A true TW201722428A (zh) 2017-07-01

Family

ID=57349100

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105134054A TW201722428A (zh) 2015-10-23 2016-10-21 用於治療急性骨髓性白血病(aml)之醫藥組成物及對有此需要者進行急性骨髓性白血病治療之方法

Country Status (8)

Country Link
US (1) US20180303812A1 (https=)
EP (1) EP3364966A1 (https=)
JP (1) JP2018538247A (https=)
KR (1) KR20180067677A (https=)
CN (1) CN108135884A (https=)
HK (1) HK1253320A1 (https=)
TW (1) TW201722428A (https=)
WO (1) WO2017069288A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
CN119280393A (zh) * 2018-10-30 2025-01-10 宏观基因有限公司 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
CN111893172A (zh) * 2020-06-24 2020-11-06 南通大学附属医院 Grsf1在判断脓毒症患者严重程度及预后方面的应用
CN115992226B (zh) * 2021-10-19 2024-10-01 上海交通大学医学院附属新华医院 检测c1q表达水平的试剂在制备急性髓细胞白血病诊断或预后判断及治疗试剂中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120561A2 (en) 2008-03-22 2009-10-01 Merck & Co., Inc. Methods and gene expression signature for assessing growth factor signaling pathway regulation status
AU2012226890B2 (en) * 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US20160333419A1 (en) * 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors

Also Published As

Publication number Publication date
US20180303812A1 (en) 2018-10-25
KR20180067677A (ko) 2018-06-20
EP3364966A1 (en) 2018-08-29
CN108135884A (zh) 2018-06-08
WO2017069288A1 (en) 2017-04-27
WO2017069288A8 (en) 2018-04-12
JP2018538247A (ja) 2018-12-27
HK1253320A1 (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
US11672774B2 (en) Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
EP3198035B1 (en) Methods for predicting drug responsiveness
EP1751309B1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
US9410206B2 (en) Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer
TW201722428A (zh) 用於治療急性骨髓性白血病(aml)之醫藥組成物及對有此需要者進行急性骨髓性白血病治療之方法
US20080312199A1 (en) Treatments of therapy resistant diseases and drug combinations for treating the same
EP2041575A2 (en) Prognostic and diagnostic method for cancer therapy
US20090098538A1 (en) Prognostic and diagnostic method for disease therapy
CN103261413B (zh) 三剂并用抗癌剂感受性判定标记
WO2013052480A1 (en) Marker-based prognostic risk score in colon cancer
CA2660857A1 (en) Prognostic and diagnostic method for disease therapy
WO2022053065A1 (zh) 用于预测或评估肺癌患者的生物标志物、检测方法及应用
CN102325905B (zh) 伊立替康的敏感性判断方法及其利用
US20220002396A1 (en) Methods of treating cancer with farnesyltransferase inhibitors
EP2655661B1 (en) Methods and means for molecular classification of colorectal cancers
US20140329714A1 (en) Stat3 activation as a marker for classification and prognosis of dlbcl patients
JP2024508633A (ja) Msi癌を診断する方法
JP2006520197A (ja) チミジレートシンターゼ遺伝子座におけるヘテロ接合性の喪失に基づいて化学療法計画を決定する方法
US20230248683A1 (en) Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20250305059A1 (en) Predictive biomarkers in colorectal cancer
WO2024192107A1 (en) Germline and cancer subtypes for monitoring and treatment
WO2023009173A1 (en) Methods for selecting melanoma patients for therapy and methods of reducing or preventing melanoma metastasis
HK1092183A (en) Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus